Quick Summary
- Mortality Reduction: MAT with buprenorphine or methadone reduces all-cause mortality in Opioid Use Disorder by approximately 50%, according to a 2020 Lancet meta-analysis.
- Retention: Patients on MAT are 75% more likely to remain in treatment compared to behavioral-only approaches.
- Not "Replacing One Drug With Another": MAT medications stabilize brain chemistry without producing euphoria at therapeutic doses, enabling normal cognitive and emotional function.
What Is Medication-Assisted Treatment?
MAT is the combination of pharmacological treatment with psychosocial interventions (individual therapy, group counseling, and support groups). The medication component addresses the biological dimension of addiction — cravings, withdrawal, and neurochemical imbalances — while therapy addresses the behavioral, psychological, and social dimensions. Neither component alone is as effective as both combined.
MAT Medications for Opioid Use Disorder
Buprenorphine (Suboxone, Sublocade): A partial opioid agonist that binds opioid receptors enough to prevent withdrawal and cravings without producing significant euphoria. Available as sublingual films, tablets, and monthly injectable (Sublocade). Can be prescribed by waivered physicians in office-based settings.
Methadone: A full opioid agonist administered daily at licensed Opioid Treatment Programs (OTPs). Most effective for severe, treatment-resistant opioid addiction. Requires daily clinic visits initially, with take-home privileges earned through compliance.
Naltrexone (Vivitrol): An opioid antagonist that completely blocks opioid receptors. Available as a monthly injection. Requires full detox before initiation (7–14 days opioid-free). Best suited for highly motivated patients who have already completed detox.
MAT Medications for Alcohol Use Disorder
Naltrexone (Revia/Vivitrol): Blocks the opioid-mediated "reward" from alcohol, reducing the pleasurable effects and thereby decreasing the desire to drink. Available as daily oral tablet or monthly injection.
Acamprosate (Campral): Restores the balance between excitatory and inhibitory neurotransmitter systems disrupted by chronic alcohol use. Reduces post-acute withdrawal symptoms like anxiety, insomnia, and dysphoria that drive relapse.
Disulfiram (Antabuse): Creates an intensely unpleasant physical reaction (flushing, nausea, headache, rapid heartbeat) if alcohol is consumed. Works through aversion conditioning but requires high patient motivation and compliance.
Addressing the Stigma
The most common criticism of MAT — that it "replaces one drug with another" — reflects a fundamental misunderstanding of pharmacology. Therapeutic doses of buprenorphine and methadone do not produce euphoria; they normalize brain chemistry so patients can function, work, parent, and engage in therapy. The evidence is unambiguous: MAT saves lives. Withholding it based on philosophical objections is clinically and ethically unjustifiable.
Frequently Asked Questions
How long should I stay on MAT?
+
There is no universally recommended duration. SAMHSA recommends a minimum of one year for opioid use disorder, and many patients benefit from indefinite maintenance. Premature discontinuation is the single largest risk factor for relapse and overdose death. The decision to taper should be made collaboratively with your prescriber based on stability, support, and readiness.
Can I get Suboxone from my regular doctor?
+
As of 2023, the MATE Act eliminated the X-waiver requirement. Any DEA-registered practitioner with a valid controlled substances license can now prescribe buprenorphine for opioid use disorder. This dramatically expanded access to office-based MAT.
Does MAT show up on a drug test?
+
Standard workplace drug tests do not screen for buprenorphine or methadone. Specialized panels can detect them, but prescribed MAT is a legitimate medical treatment protected under the ADA. Your employer cannot discriminate against you for taking prescribed medication for a documented medical condition.
Sources
RehabSearch cites peer-reviewed research and recognized health organizations.
- SAMHSA. "Medication-Assisted Treatment (MAT)." samhsa.gov, 2023.
- The Lancet. "Mortality among patients in opioid agonist treatment: meta-analysis." 2020.
- NIDA. "Medications to Treat Opioid Use Disorder." drugabuse.gov, 2021.